MAP1LC3B2

Across TCGA pan-cancer cohorts, MAP1LC3B2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MAP1LC3B2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MAP1LC3B2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP1LC3B2 expression acts as an unfavorable survival marker.

HNSC are the cancer types where MAP1LC3B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.051	0.726	<.001	42	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

MAP1LC3B2–HNSC (OS)

Open the HNSC breakdown →